Vial Logo

Next-Generation Pharma Company

Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need

Get in touch

Pipeline

TL1A HLE

Phase I
TL1A-VIAL-HLE has started a phase 1 trial and remains on track to have an interim data readout in 2Q25 and a final readout in 3Q25

Indication

Inflammatory bowel disease (IBD)

Next Data Catalyst

Interim data readout in 2Q25
Read Press Release

IL-13 x TSLP

Preclinical

Indication

Atopic Dermatitis, Asthma, Chronic Sinusitis

Est. Ph I Initiation

H2 2025

Myostatin (GDF-8) x Activin-A

Preclinical

Indication

Obesity

Est. Ph I Initiation

H2 2025

a4B7 x IL-23

Preclinical

Indication

Inflammatory bowel disease (IBD)

Est. Ph I Initiation

H2 2025

IL-23 x TL1A

Preclinical

Indication

Inflammatory bowel disease (IBD)

Est. Ph I Initiation

H2 2025
Get in touch

Our model is powered by a computational discovery engine and highly automated clinical trials

molecule-icon

Computationally Enabled Discovery.

Computationally enabled discovery platform delivers programs with best-in-class, differentiated profiles at-scale.

Automated Clinical Trials.

Leveraging technology to automate clinical trials, enhancing precision and efficiency in drug development.

Recent News

Press Releases

Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial of a Novel Subcutaneous Half-life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases

Read Article

Open Positions

Join our team in reimagining drug development.
Explore Roles